vs

Side-by-side financial comparison of HARVARD BIOSCIENCE INC (HBIO) and Waters Corporation (WAT). Click either name above to swap in a different company.

Waters Corporation is the larger business by last-quarter revenue ($932.4M vs $23.7M, roughly 39.3× HARVARD BIOSCIENCE INC). Waters Corporation runs the higher net margin — 24.2% vs -12.0%, a 36.2% gap on every dollar of revenue. On growth, Waters Corporation posted the faster year-over-year revenue change (6.8% vs -3.3%). Over the past eight quarters, Waters Corporation's revenue compounded faster (21.0% CAGR vs -1.6%).

Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.

Waters Corporation is an American company headquartered in Milford, Massachusetts that provides analytical instruments and software used for chromatography, mass spectrometry, laboratory informatics, and rheometry by the life sciences, materials, and food industries.

HBIO vs WAT — Head-to-Head

Bigger by revenue
WAT
WAT
39.3× larger
WAT
$932.4M
$23.7M
HBIO
Growing faster (revenue YoY)
WAT
WAT
+10.2% gap
WAT
6.8%
-3.3%
HBIO
Higher net margin
WAT
WAT
36.2% more per $
WAT
24.2%
-12.0%
HBIO
Faster 2-yr revenue CAGR
WAT
WAT
Annualised
WAT
21.0%
-1.6%
HBIO

Income Statement — Q4 2025 vs Q4 2025

Metric
HBIO
HBIO
WAT
WAT
Revenue
$23.7M
$932.4M
Net Profit
$-2.8M
$225.2M
Gross Margin
59.7%
61.1%
Operating Margin
7.2%
29.0%
Net Margin
-12.0%
24.2%
Revenue YoY
-3.3%
6.8%
Net Profit YoY
-15916.7%
-2.7%
EPS (diluted)
$-0.06
$3.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HBIO
HBIO
WAT
WAT
Q4 25
$23.7M
$932.4M
Q3 25
$20.6M
$799.9M
Q2 25
$20.4M
$771.3M
Q1 25
$21.8M
$661.7M
Q4 24
$24.6M
$872.7M
Q3 24
$22.0M
$740.3M
Q2 24
$23.1M
$708.5M
Q1 24
$24.5M
$636.8M
Net Profit
HBIO
HBIO
WAT
WAT
Q4 25
$-2.8M
$225.2M
Q3 25
$-1.2M
$148.9M
Q2 25
$-2.3M
$147.1M
Q1 25
$-50.3M
$121.4M
Q4 24
$18.0K
$231.4M
Q3 24
$-4.8M
$161.5M
Q2 24
$-2.9M
$142.7M
Q1 24
$-4.7M
$102.2M
Gross Margin
HBIO
HBIO
WAT
WAT
Q4 25
59.7%
61.1%
Q3 25
58.4%
59.0%
Q2 25
56.4%
58.3%
Q1 25
56.0%
58.2%
Q4 24
57.1%
60.1%
Q3 24
58.1%
59.3%
Q2 24
57.2%
59.3%
Q1 24
60.3%
58.9%
Operating Margin
HBIO
HBIO
WAT
WAT
Q4 25
7.2%
29.0%
Q3 25
1.0%
24.0%
Q2 25
-4.0%
24.4%
Q1 25
-228.1%
22.9%
Q4 24
0.0%
33.5%
Q3 24
-8.5%
28.5%
Q2 24
-9.0%
26.7%
Q1 24
-9.3%
21.0%
Net Margin
HBIO
HBIO
WAT
WAT
Q4 25
-12.0%
24.2%
Q3 25
-6.0%
18.6%
Q2 25
-11.2%
19.1%
Q1 25
-231.2%
18.3%
Q4 24
0.1%
26.5%
Q3 24
-21.9%
21.8%
Q2 24
-12.7%
20.1%
Q1 24
-19.1%
16.0%
EPS (diluted)
HBIO
HBIO
WAT
WAT
Q4 25
$-0.06
$3.76
Q3 25
$-0.03
$2.50
Q2 25
$-0.05
$2.47
Q1 25
$-1.14
$2.03
Q4 24
$0.01
$3.88
Q3 24
$-0.11
$2.71
Q2 24
$-0.07
$2.40
Q1 24
$-0.11
$1.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HBIO
HBIO
WAT
WAT
Cash + ST InvestmentsLiquidity on hand
$8.6M
$587.8M
Total DebtLower is stronger
$35.9M
$1.4B
Stockholders' EquityBook value
$13.7M
$2.6B
Total Assets
$80.1M
$5.1B
Debt / EquityLower = less leverage
2.61×
0.55×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HBIO
HBIO
WAT
WAT
Q4 25
$8.6M
$587.8M
Q3 25
$6.8M
$459.1M
Q2 25
$7.4M
$367.2M
Q1 25
$5.5M
$382.9M
Q4 24
$4.1M
$325.4M
Q3 24
$4.6M
$331.5M
Q2 24
$4.0M
$327.4M
Q1 24
$4.3M
$338.2M
Total Debt
HBIO
HBIO
WAT
WAT
Q4 25
$35.9M
$1.4B
Q3 25
$34.0M
Q2 25
$34.9M
Q1 25
$36.4M
Q4 24
$37.0M
$1.6B
Q3 24
$34.9M
Q2 24
$35.7M
Q1 24
$35.6M
Stockholders' Equity
HBIO
HBIO
WAT
WAT
Q4 25
$13.7M
$2.6B
Q3 25
$14.1M
$2.3B
Q2 25
$15.7M
$2.2B
Q1 25
$14.8M
$2.0B
Q4 24
$63.3M
$1.8B
Q3 24
$65.3M
$1.6B
Q2 24
$67.2M
$1.4B
Q1 24
$68.8M
$1.3B
Total Assets
HBIO
HBIO
WAT
WAT
Q4 25
$80.1M
$5.1B
Q3 25
$78.0M
$4.9B
Q2 25
$80.1M
$4.7B
Q1 25
$79.8M
$4.6B
Q4 24
$126.6M
$4.6B
Q3 24
$131.2M
$4.5B
Q2 24
$128.9M
$4.4B
Q1 24
$133.2M
$4.5B
Debt / Equity
HBIO
HBIO
WAT
WAT
Q4 25
2.61×
0.55×
Q3 25
2.41×
Q2 25
2.22×
Q1 25
2.45×
Q4 24
0.58×
0.89×
Q3 24
0.53×
Q2 24
0.53×
Q1 24
0.52×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HBIO
HBIO
WAT
WAT
Operating Cash FlowLast quarter
$-96.0K
$164.6M
Free Cash FlowOCF − Capex
$-545.0K
FCF MarginFCF / Revenue
-2.3%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
0.73×
TTM Free Cash FlowTrailing 4 quarters
$5.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HBIO
HBIO
WAT
WAT
Q4 25
$-96.0K
$164.6M
Q3 25
$1.1M
$187.3M
Q2 25
$2.8M
$41.1M
Q1 25
$3.0M
$259.6M
Q4 24
$1.7M
$240.1M
Q3 24
$-842.0K
$204.6M
Q2 24
$-846.0K
$54.5M
Q1 24
$1.4M
$262.9M
Free Cash Flow
HBIO
HBIO
WAT
WAT
Q4 25
$-545.0K
Q3 25
$877.0K
Q2 25
$2.7M
Q1 25
$2.5M
Q4 24
$1.4M
Q3 24
$-1.7M
Q2 24
$-1.7M
Q1 24
$758.0K
FCF Margin
HBIO
HBIO
WAT
WAT
Q4 25
-2.3%
Q3 25
4.3%
Q2 25
13.0%
Q1 25
11.4%
Q4 24
5.8%
Q3 24
-7.8%
Q2 24
-7.2%
Q1 24
3.1%
Capex Intensity
HBIO
HBIO
WAT
WAT
Q4 25
1.9%
Q3 25
1.0%
Q2 25
0.4%
Q1 25
2.4%
Q4 24
1.2%
Q3 24
4.0%
Q2 24
3.5%
Q1 24
2.6%
Cash Conversion
HBIO
HBIO
WAT
WAT
Q4 25
0.73×
Q3 25
1.26×
Q2 25
0.28×
Q1 25
2.14×
Q4 24
95.83×
1.04×
Q3 24
1.27×
Q2 24
0.38×
Q1 24
2.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HBIO
HBIO

Instruments Equipment Software And Accessories$21.6M91%
Service Maintenance And Warranty Contracts$2.1M9%

WAT
WAT

Segment breakdown not available.

Related Comparisons